Skysis | CASE STUDY
Commercial Planning
01 | BACKGROUND
Clinical development-stage companies understand that foundational commercial activities must be contemporaneous with IND (investigational new drug) acceptance, and commencement of the first clinical trial. These foundational commercial activities are important inputs into both the design of a mid- and late-stage clinical development program and the initial valuation of assets that have reached the clinical development stage.
02 | CHALLENGE
At the point of IND acceptance, many clinical-development stage companies remain ‘scientifically focused’ and do not have the commercial capability to complete this early and important commercial work.
03 | METHODOLOGY
Skysis leverages several proprietary offerings including: i) product concept decision support analysis (Skysis I.D.E.A); senior-executive level launch plan (Skysis Commercial Sketch); and a detailed operational launch plan that includes linking all cross-functional interdependencies within a project management platform (Commercialization Blueprint). Based on the stage of development and a client’s commercial management needs, Skysis generates a comprehensive list of commercial strategy and market access activities that include sequencing, timelines, and integrated workstreams. Skysis is uniquely positioned to both manage the commercial function in clinical-development stage companies and complete the foundational commercial activities with our team of commercial strategy and market access experts.
04 | OUTCOME
Early in clinical development. Skysis’ clients understand the full inventory of commercial activities and their sequencing, timing, and integration with the workstreams of other functions. Many clients have engaged Skysis to complete their foundational commercial activities and manage their commercial functions prior to handing them off to the company’s commercial team later in clinical development.
